COVID-19 Containment: China Provides Important Lessons for Global Response
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Treatment with Convalescent Plasma for COVID‐19 Patients in Wuhan
Tangfeng Lv ORCID iD: 0000-0001-7224-8468 Treatment with convalescent plasma for COVID-19 patients in Wuhan, China Mingxiang Ye, MD, PhD Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China Dian Fu, MD Department of Urology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China Yi Ren, MD Department of Emergency, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jmv.25882. Accepted Article This article is protected by copyright. All rights reserved. Faxiang Wang, MD Department of Emergency, 904 Hospital, Wuxi, China Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China Dong Wang, MD, PhD Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China Fang Zhang, MD Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China Xinyi Xia, MD Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China Department of Laboratory Medicine, Wuhan Huoshenshan Hospital, Wuhan, China Accepted Article This article is protected by copyright. -
Policy Disparities in Response to the First Wave of COVID-19 Between China and Germany Yuyao Zhang1, Leiyu Shi2, Haiqian Chen1, Xiaohan Wang1 and Gang Sun1,2*
Zhang et al. International Journal for Equity in Health (2021) 20:86 https://doi.org/10.1186/s12939-021-01424-3 RESEARCH Open Access Policy disparities in response to the first wave of COVID-19 between China and Germany Yuyao Zhang1, Leiyu Shi2, Haiqian Chen1, Xiaohan Wang1 and Gang Sun1,2* Abstract Objective: Our research summarized policy disparities in response to the first wave of COVID-19 between China and Germany. We look forward to providing policy experience for other countries still in severe epidemics. Methods: We analyzed data provided by National Health Commission of the People’s Republic of China and Johns Hopkins University Coronavirus Resource Center for the period 10 January 2020 to 25 May 252,020. We used generalized linear model to evaluate the associations between the main control policies and the number of confirmed cases and the policy disparities in response to the first wave of COVID-19 between China and Germany. Results: The generalized linear models show that the following factors influence the cumulative number of confirmed cases in China: the Joint Prevention and Control Mechanism; locking down the worst-hit areas; the highest level response to public health emergencies; the expansion of medical insurance coverage to suspected patients; makeshift hospitals; residential closed management; counterpart assistance. The following factors influence the cumulative number of confirmed cases in Germany: the Novel Coronavirus Crisis Command; large gathering cancelled; real-time COVID-19 risk assessment; the medical emergency plan; schools closure; restrictions on the import of overseas epidemics; the no-contact protocol. Conclusions: There are two differences between China and Germany in non-pharmaceutical interventions: China adopted the blocking strategy, and Germany adopted the first mitigation and then blocking strategy; China’s goal is to eliminate the virus, and Germany’s goal is to protect high-risk groups to reduce losses. -
CONNECTION the Official Newsletter of Zhejiang University Issue 16 Feb.2020
CONNECTION The Official Newsletter of Zhejiang University Issue 16 Feb.2020 COVID-19 Special Issue Stand Strong Message from Editor-in-Chief CONNECTION Welcome to the special COVID-19 issue of Issue 16 CONNECTION, which highlights the efforts and contributions of ZJU community in face of the epidemic. As a group, they are heroes in harm's way, givers and doers who respond swiftly to the need of our city, our country and the world. When you read their stories, you'll recognize the strength and solidarity that define all ZJUers. ZJU community has demonstrated its courage and resilience in the battle against the novel coronavirus. At this time, let us all come together to protect ourselves and our loved ones, keep all those who are at the front lines in our prayers and pass on our gratitude to those who have joined and contributed to the fight against the virus. Together, we will weather this crisis. LI Min, Editor-in-Chief Director, Office of Global Engagement Editorial office : Global Communications Office of Global Engagement, Zhejiang University 866 Yuhangtang Road, Hangzhou, P.R. China 310058 Phone: +86 571 88981259 Fax: +86 571 87951315 Email: [email protected] Edited by : CHEN Weiying, AI Ni Designed by : HUANG Zhaoyi Material from Connection may be reproduced accompanied with appropriate acknowledgement. CONTENTS Faculty One of the heroes in harm’s way: LI Lanjuan 03 ZJU medics answered the call from Wuhan 04 Insights from ZJU experts 05 Alumni Fund for Prevention and Control of Viral Infectious Diseases set up 10 Alumni community mobilized in the battle against COVID-19 11 Education Classes start online during the epidemic 15 What ZJUers feel about online learning 15 Efforts to address concerns, avoid misinformation 17 International World standing with us 18 International students lending a hand against the epidemic 20 What our fans say 21 FacultyFaculty ZJU community has taken on the responsibility to join the concertedZJU community efforts has takenagainst on thethe responsibility spreadto join the of concerted the virus. -
1. Sars-Cov Nucleocapsid Protein Epitopes and Uses Thereof
www.engineeringvillage.com Citation results: 500 Downloaded: 4/24/2020 1. SARS-COV NUCLEOCAPSID PROTEIN EPITOPES AND USES THEREOF KELVIN, David; PERSAD, Desmond; CAMERON, Cheryl; BRAY, Kurtis, R.; LOFARO, Lori, R.; JOHNSON, Camille; SEKALY, Rafick-Pierre; YOUNES, Souheil-Antoine; CHONG, Pele Assignee: UNIVERSITY HEALTH NETWORK; BECKMAN COULTER, INC.; UNIVERSITE DE MONTREAL; NATIONAL HEALTH RESEARCH INSTITUTES Publication Number: WO2005103259 Publication date: 11/03/2005 Kind: Patent Application Publication Database: WO Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data Provider: Engineering Village 2. SARS-CoV-specific B-cell epitope and applications thereof Wu, Han-Chung; Liu, I-Ju; Chiu, Chien-Yu Assignee: National Taiwan University Publication Number: US20060062804 Publication date: 03/23/2006 Kind: Utility Patent Application Database: US Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data Provider: Engineering Village 3. A RECOMBINANT SARS-COV VACCINE COMPRISING ATTENUATED VACCINIA VIRUS CARRIERS QIN, Chuan; WEI, Qiang; GAO, Hong; TU, Xinming; CHEN, Zhiwei; ZHANG, Linqi; HO, David, D. Assignee: INSTITUTE OF LABORATORY ANIMAL SCIENCE OF CHINESE ACADEMY OF MEDICAL SCIENCES; THE AARON DIAMOND AIDS RESEARCH CENTER; QIN, Chuan; WEI, Qiang; GAO, Hong; TU, Xinming; CHEN, Zhiwei; ZHANG, Linqi; HO, David, D. Publication Number: WO2006079290 Publication date: 08/03/2006 Kind: Patent Application Publication Database: WO Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data -
Read More In
Contents Abstract ......................................................................................................................... 2 Introduction .................................................................................................................. 3 I. Facing COVID-19 – the Common Enemy .............................................................. 4 II. Taking Measures Suitable to National Circumstances ........................................ 6 2.1 China’s Intensive Combat against COVID-19 ................................................. 6 2.2 The “Protracted War” in Europe ...................................................................... 8 III. Working Together to Fight the Common Enemy ............................................. 14 3.1 Building Confidence through Mutual Support .............................................. 14 3.2 Sharing Experience to Improve Patient Treatment ........................................ 19 3.3 Providing Supplies in the Spirit of Reciprocity ............................................. 23 IV. Building a Community of Shared Future .......................................................... 27 4.1 Overcoming Prejudices .................................................................................. 27 4.2 Protecting the Economy and People’s Livelihood ......................................... 34 4.3 Working Together to Advance Post-Pandemic Development ........................ 37 Conclusion ................................................................................................................. -
COVID-19 and Infectious Diseases
World Scientific Titles on COVID-19 and Infectious Diseases GET THIS SPECIAL EBOOK PACKAGE ON COVID-19 AND INFECTIOUS DISEASES FOR YOUR INSTITUTION’S USE, AVAILABLE UNTIL MARCH 2021! Original price US$2,384 / GBP 2,020 Packaged price US$1,668 / GBP 1,415 Prevention and Control Hydrogen-Oxygen of COVID-19 Inhalation for Treatment Editor-in-chief Wenhong Zhang for COVID-19 (Huashan Hospital of Fudan University, With Commentary China) from Zhong Nashan by Kecheng Xu “World Scientific is to be congratulated (Jinan University, China) for rapidly pulling together a book written and edited by the Chinese teams who first COVID-19 pneumonia is ravaging the experienced and managed the Covid 19 world. Faced with the lack of specialized outbreak. This book’s free access is so treatment, a novel form of hydrogen- commendable, thus inevitably and rightly oxygen inhalation therapy has been increasing access to all; an excellent successfully developed. Molecular repository of up to date knowledge on the hydrogen, a very safe "physiological gas", greatest health challenge of our generation.” has proven to be able to reduce lung damage caused by viruses including COVID-19, improve dyspnea, and promote disease J Richard Smith recovery due to its healing biological properties. Imperial College, London, UK This book details an innovative form of treatment from theory to Shanghai COVID-19 Medical Treatment Expert Team edits this practice, and comprehensively discusses the rationality of this new timely guide for effective prevention and control of COVID-19. treatment for COVID-19 pneumonia. It is ideal not only for doctors, Readers will obtain useful guidance on prevention and control but also for the general public, as it provides new knowledge and of COVID-19 in different places ranging from homes, outdoors, effective treatment and rehabilitation methods to combat this highly workplaces, etc. -
Evaluating the Association of Clinical Characteristics with Neutralizing Antibody Levels in Patients Who Have Recovered from Mild COVID-19 in Shanghai, China
Research JAMA Internal Medicine | Original Investigation Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China Fan Wu, PhD; Mei Liu, MS; Aojie Wang, MS; Lu Lu, PhD; Qimin Wang, MS; Chenjian Gu, MS; Jun Chen, MD; Yang Wu, MS; Shuai Xia, PhD; Yun Ling, MD; Yuling Zhang, MS; Jingna Xun, MS; Rong Zhang, PhD; Youhua Xie, PhD; Shibo Jiang, MD, PhD; Tongyu Zhu, MD; Hongzhou Lu, MD; Yumei Wen, MD; Jinghe Huang, PhD Editor's Note page 1362 IMPORTANCE The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute Supplemental content respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The association between clinical characteristics of the virus and neutralizing antibodies (NAbs) against this virus have not been well studied. OBJECTIVE To examine the association between clinical characteristics and levels of NAbs in patients who recovered from COVID-19. DESIGN, SETTING, AND PARTICIPANTS In this cohort study, a total of 175 patients with mild symptoms of COVID-19 who were hospitalized from January 24 to February 26, 2020, were followed up until March 16, 2020, at Shanghai Public Health Clinical Center, Shanghai, China. EXPOSURES SARS-CoV-2 infections were diagnosed and confirmed by reverse transcriptase–polymerase chain reaction testing of nasopharyngeal samples. MAIN OUTCOMES AND MEASURES The primary outcome was SARS-CoV-2–specific NAb titers. Secondary outcomes included spike-binding antibodies, cross-reactivity against SARS-associated CoV, kinetics of NAb development, and clinical information, including age, sex, disease duration, length of stay, lymphocyte counts, and blood C-reactive protein level. -
Emergency Architecture. Modular Construction of Healthcare Facilities As a Response to Pandemic Outbreak
E3S Web of Conferences 274, 01013 (2021) https://doi.org/10.1051/e3sconf/202127401013 STCCE – 2021 Emergency architecture. Modular construction of healthcare facilities as a response to pandemic outbreak Marina Smolova1, and Daria Smolova2[0000-0002-2297-0505] 1Kazan State University of Architecture and Engineering, 420043 Kazan, Russia 2NFOE Inc., QC H2Y 2W7 Montreal, Canada Abstract. Emerging infectious diseases originating from wildlife species continue to demolish humankind leaving an imprint on human history. December 2019 has marked the emergence of a novel coronavirus named SARS-CoV-2 (Covid-2019) originated in China in the city of Wuhan. Drastic emergence and spread of infectious disease have shown to appear in highly densified areas causing rapid spread of epidemic through population movement, transmission routes, major activity nodes, proximity, and connectivity of urban spaces. An extreme number of cases rising throughout the world caused space unavailability in healthcare facilities to serve patients infected with Covid-2019, therefore urging for innovative emergency management response from construction and architecture industry. Prefabricated modular construction has been widely utilized around the globe assembling rapid response facilities after catastrophic events such as tornadoes, hurricanes, and forest fires. An increasing number of Covid-2019 cases demanded effective and compressed implementation of medical centres to provide expeditious and secure healthcare. The paper examines the potential of standardization of modular construction of hospitals as a response to current and potential pandemic outbreaks. The research provides fundamental planning requirements of isolation units and their design flexibility as a key to rapid emergency solution. Keywords. Modular construction, prefabrication, prefabricated construction, emergency architecture, healthcare facilities, hospitals, prefabricated architecture, Covid-2019. -
Lopinavir/Ritonavir for COVID-19: a Living Systematic Review Doi: 10.5867/Medwave.2020.06.7966
Lopinavir/ritonavir for COVID-19: A living systematic review doi: 10.5867/medwave.2020.06.7966 Appendix 3: Included, excluded and ongoing studies - Lopinavir/ritonavir for COVID-19: A living systematic review Included randomised trials LOTUS China (1,2) Details or comments REFERENCES Publication thread for LOTUS China Epistemonikos Chen et al (1) Type: Journal article Epistemonikos | DOI ChiCTR2000029387 (2) Type:Trial registry (Chinese Clinical Trial Registry) Epistemonikos | DOI (not available) STUDY DESIGN QUOTE: ☑Randomised trial Single centre , open-label, individually randomized, controlled trial; ☐Comparative, non- randomised Eligible patients were randomly assigned in a 1:1 ratio; ☐Non-comparative study To balance the distribution of oxygen support between the two groups as an indicator of severity of respiratory failure, randomization was stratified on the basis of respiratory support methods at the time of enrollment: no oxygen support or oxygen support with nasal duct or mask, or high-flow oxygen, noninvasive ventilation, or invasive ventilation including ECMO. The permuted block (four patients per block) randomization sequence, including stratification, was prepared by a statistician not involved in the trial, using SAS software, version 9.4 (SAS Institute). POPULATION: INCLUSION QUOTE: CRITERIA Patients were assessed for eligibility on the basis of a positive reverse-transcriptase– ☐COVID-19 polymerase-chain-reaction (RT-PCR) assay) for SARS-CoV-2 in a respiratory tract ☑COVID-19 pneumonia sample Male and nonpregnant female patients 18 years of age or older were eligible if they had a diagnostic specimen that was positive on RT-PCR, had pneumonia ☐Severe COVID-19 pneumonia confirmed by chest imaging, had an oxygen saturation of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen to the fraction 1 / 27 Lopinavir/ritonavir for COVID-19: A living systematic review doi: 10.5867/medwave.2020.06.7966 of inspired oxygen at or below 300 mg Hg. -
Clinical Course and Risk Factors for In-Hospital Death in Critical COVID-19 in Wuhan, China
medRxiv preprint doi: https://doi.org/10.1101/2020.09.26.20189522; this version posted September 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Clinical Course And Risk Factors For In-hospital Death In Critical COVID-19 In Wuhan, China Fei Li, MD, PhD1,2#, Yue Cai, MD1,2#, Chao Gao, MD, PhD1#, Lei Zhou, MD, PhD2,3#, Renjuan Chen, MD, PhD1, Kan Zhang, MD1,2, Weiqin Li, MD2,4, Ruining Zhang, MD1, Xijing Zhang, MD, PhD2,5, Duolao Wang, PhD 6*, Yi Liu, MD, PhD1*, Ling Tao, MD, PhD1* 1. Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an, China 2. Huoshenshan Hospital, Wuhan, China 3. Clinical Laboratory, Xijing Hospital, Fourth Military Medical University, Xi’an, China 4. Department of Critical Care Medicine, Jinling Hospital, Nanjing, China 5. Surgical ICU, Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi’an, China 6. Department of Clinical Sciences Liverpool School of Tropical Medicine Pembroke, Liverpool, United Kingdom Address for correspondence: Professor Ling Tao, MD, PhD. Professor of Cardiology – Xijing hospital, Xi’an, China 127 Changle west road, Xi’an, 710032, China Email: [email protected] Professor Yi Liu, MD, PhD. Professor of Cardiology – Xijing hospital, Xi’an, China 127 Changle west road, Xi’an, 710032, China Email: liuyimeishan@hotmail,.com 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. -
COVID-19 Publications - Week 33 2020 804 Publications
Update August 10 - August 16, 2020, Dr. Peter J. Lansberg MD, PhD Weekly COVID-19 Literature Update will keep you up-to-date with all recent PubMed publications categorized by relevant topics COVID-19 publications - Week 33 2020 804 Publications PubMed based Covid-19 weekly literature update For those interested in receiving weekly updates click here For questions and requests for topics to add send an e-mail [email protected] Reliable on-line resources for Covid 19 WHO Cochrane Daily dashbord BMJ Country Guidance The Lancet Travel restriction New England Journal of Medicine Covid Counter JAMA Covid forcasts Cell CDC Science AHA Oxford Universtiy Press ESC Cambridge Univeristy Press EMEA Springer Nature Evidence EPPI Elsevier Wikipedia Wiley Cardionerds - COVID-19 PLOS Genomic epidemiology LitCovid NIH-NLM Oxygenation Ventilation toolkit SSRN (Pre-prints) German (ICU) bed capacity COVID reference (Steinhauser Verlag) COVID-19 Projections tracker AAN - Neurology resources COVID-19 resources (Harvard) COVID-19 resources (McMasters) COVID-19 resources (NHLBI) COVID-19 resources (MEDSCAPE) COVID-19 Diabetes (JDRF) COVID-19 TELEMEDICINE (BMJ) Global Causes of death (Johns Hopkins) COVID-19 calculators (Medscap) Guidelines NICE Guidelines Covid-19 Korean CDC Covid-19 guidelines Flattening the curve - Korea IDSA COVID-19 Guidelines Airway Management Clinical Practice Guidelines (SIAARTI/EAMS, 2020) ESICM Ventilation Guidelines Performing Procedures on Patients With Known or Suspected COVID-19 (ASA, 2020) OSHA Guidance on Preparing the Workplace -
China's Strategies and Actions Against COVID-19 and Key Insights
China’s Strategies and Actions Against COVID-19 and Key Insights Liu Chen Chen Xiao Working Paper CIKD-WP-2020-006 EN China’s Strategies and Actions Against COVID-19 and Key Insights Liu Chen Chen Xiao Author Bios Liu Chen is a Project Officer of China Center for International Knowledge on Development (CIKD). Chen Xiao is an Assistant Research Fellow of CIKD. Acknowledgement Many thanks to the colleagues in CIKD who provided very good suggestions and comments during the research. Disclaimer The findings, interpretations and conclusions expressed in this report do not necessarily reflect the views of CIKD. Contents Executive Summary ..................................................................................... i 1. Overall Strategy ...................................................................................... 2 1) Constantly refine the strategies based on the latest risk assessment and development trend of the epidemic ............................................. 2 2) Adhere to the people-centered concept, prioritize the protection of people’s right to life and health in a major epidemic, ensure the public’s right to know, and mobilize the people to participate widely ................. 9 3) Adopt the most rigorous, most comprehensive, and most complete principles and objectives .................................................................. 11 2. Key Measures ........................................................................................ 12 1) Establish national-level command and decision-making institutions